Related Experiment Video
Updated: Aug 15, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder
1Edinburgh Cancer Centre, Western General Hospital, Edinburgh, Scotland, UK. duncan.mclaren@luht.scot.nhs.uk
Abstract:
Neoadjuvant chemotherapy in transitional-cell carcinoma of the bladder (TCC) improves survival. This is one of the most important developments in the management of muscle-invasive bladder cancer in recent times. There is an improved absolute 5-year survival of at least 5% for T2-T4 disease. To achieve this benefit, a cisplatin-containing combination is required. There is no difference in survival whether radical radiotherapy or radical cystectomy is given as subsequent definitive treatment.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Imaging Studies III: Computed Tomography
Tumor Immunotherapy